Takeda Pharmaceutical (NYSE:TAK) Rating Increased to Overweight at Morgan Stanley

Takeda Pharmaceutical (NYSE:TAK) was upgraded by Morgan Stanley from an “equal weight” rating to an “overweight” rating in a research report issued on Wednesday,Finviz reports.

Takeda Pharmaceutical Trading Up 0.2 %

Shares of NYSE TAK opened at $14.91 on Wednesday. The stock has a fifty day simple moving average of $14.23 and a 200-day simple moving average of $13.92. Takeda Pharmaceutical has a twelve month low of $12.58 and a twelve month high of $15.31. The company has a current ratio of 1.31, a quick ratio of 0.72 and a debt-to-equity ratio of 0.63. The stock has a market capitalization of $47.43 billion, a PE ratio of 37.26, a PEG ratio of 0.24 and a beta of 0.46.

Takeda Pharmaceutical (NYSE:TAK) last issued its quarterly earnings results on Thursday, January 30th. The company reported $0.42 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.34 by $0.08. Takeda Pharmaceutical had a net margin of 4.53% and a return on equity of 9.39%. On average, equities analysts forecast that Takeda Pharmaceutical will post 1.64 earnings per share for the current year.

Hedge Funds Weigh In On Takeda Pharmaceutical

Several hedge funds and other institutional investors have recently added to or reduced their stakes in TAK. Versant Capital Management Inc acquired a new stake in shares of Takeda Pharmaceutical in the fourth quarter valued at $26,000. Wilmington Savings Fund Society FSB purchased a new stake in Takeda Pharmaceutical during the 3rd quarter worth about $40,000. BNP Paribas Financial Markets raised its position in Takeda Pharmaceutical by 416.0% in the 3rd quarter. BNP Paribas Financial Markets now owns 3,220 shares of the company’s stock valued at $46,000 after purchasing an additional 2,596 shares in the last quarter. Farther Finance Advisors LLC boosted its stake in shares of Takeda Pharmaceutical by 123.6% in the 4th quarter. Farther Finance Advisors LLC now owns 3,575 shares of the company’s stock valued at $47,000 after buying an additional 1,976 shares during the period. Finally, Erste Asset Management GmbH acquired a new position in shares of Takeda Pharmaceutical during the third quarter worth about $52,000. Hedge funds and other institutional investors own 9.17% of the company’s stock.

Takeda Pharmaceutical Company Profile

Takeda Pharmaceutical Company Limited engages in the research, development, manufacture, marketing, and out-licensing of pharmaceutical products in Japan and internationally. It offers pharmaceutical products in the areas of gastroenterology, rare diseases, plasma derived therapies, immunology, oncology, and neuroscience.